Acebilustat is under clinical development by Celtaxsys Inc and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Acebilustat’s likelihood of approval (LoA) and phase transition for Primary Ciliary Dyskinesia took place on 25 Nov 2020, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Acebilustat Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Acebilustat overview

Acebilustat (formerly CTX-4430, EP-501) is under development for the treatment of bullous dermatoses, upper extremity lymphedema and primary ciliary dyskinesia. CTX-4430 is a small molecule which is administered through oral and topical routes. It acts by targeting pro-inflammatory enzyme leukotriene A4 hydrolase (LTA4H).

It was also under development for the treatment of acne vulgaris, adult cystic fibrosis as an oral and topical formulation. It was under development for acne rosacea as a topical formulation. It was also under development for the treatment of gouty arthritis, hidradenitis suppurativa and non-CF bronchiectasis. and pulmonary arterial hypertension as oral formulation, and was also under development for the treatment of an unspecified indication as topical formulation.

Celtaxsys Inc overview

Celtaxsys Inc (Celtaxsys) is a clinical-stage pharmaceutical development company.

Quick View Acebilustat LOA Data

Report Segments
  • Innovator
Drug Name
  • Acebilustat
Administration Pathway
  • Oral
  • Topical
Therapeutic Areas
  • Cardiovascular
  • Dermatology
  • Hematological Disorders
  • Musculoskeletal Disorders
  • Respiratory
  • Undisclosed
Key Developers
  • Sponsor Company: Celtaxsys
  • Originator: Bayer
Highest Development Stage
  • Phase II


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.